Dr. Kemneth Borow is co-applicant with Dr. Itescu in this patent - see my post which I am replying to - in Feb 2024, on the method of treating progressive heart failure in patients at high risk of poor outcomes.
As MediMergent’s Chief Medical Officer, “Dr. Borow has been actively involved in study design development and operations as well as driving processes towards more patient centric outcomes. He has helped develop innovative ways to design and execute hybrid research programs that bridge the gap between real-world evidence and objective immunological biomarkers (including T-cell and B-cell function).”
Ann: Annual Financial Results Presentation, page-165
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |